Active Ingredient History
Dimethyl fumarate (DMF) is the methyl ester of fumaric acid and is named after the earth smoke plant. Dimethyl fumarate combined with three other fumaric acid esters (FAEs) is solely licensed in Germany as an oral therapy for psoriasis. Since 2013, it has been approved by the U.S. Food and Drug Administration (FDA) as a treatment option for adults with relapsing multiple sclerosis. In 2017, a new oral formulation of dimethyl fumarate was approved by the European Medicines Agency (EMA) for use in the European Union as a treatment for moderate-to-severe plaque psoriasis. Dimethyl fumarate is thought to have immunomodulatory properties without causing significant immunosuppression. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arthritis, Psoriatic (Phase 2)
Arthritis, Rheumatoid (Phase 2)
Cerebral Hemorrhage (Phase 2)
Glioblastoma (Phase 1)
Gliosarcoma (Phase 1)
Healthy Volunteers (Phase 3)
Hypertension, Pulmonary (Phase 1)
Ischemic Stroke (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Lymphoma, T-Cell, Cutaneous (Phase 2)
Macular Degeneration (Phase 2)
Multiple Sclerosis, Chronic Progressive (Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 4)
Psoriasis (Phase 4)
Scleroderma, Systemic (Phase 1)
Sleep Apnea, Obstructive (Phase 2)
Sleep Apnea Syndromes (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
